<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2025-407</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-9535</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>САХАРНЫЙ ДИАБЕТ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>DIABETES MELLITUS</subject></subj-group></article-categories><title-group><article-title>Предиабет – окно возможностей для профилактических вмешательств. Часть 1</article-title><trans-title-group xml:lang="en"><trans-title>Prediabetes is a window of opportunity for preventive interventions. Part 1</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3763-8994</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Адашева</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Adasheva</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Адашева Татьяна Владимировна, д.м.н., профессор кафедры терапии и профилактической медицины</p><p>127006, Россия, Москва, ул. Долгоруковская, д. 4</p></bio><bio xml:lang="en"><p>Tatiana V. Adasheva, Dr. Sci. (Med.), Professor of the Department of Therapy and Preventive Medicine</p><p>4, Dolgorukovskaya St., Moscow, 127006, Russia</p></bio><email xlink:type="simple">adashtv@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-4149-9497</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Губернаторова</surname><given-names>Е. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Gubernatorova</surname><given-names>E. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Губернаторова Екатерина Евгеньевна, к.м.н., ассистент кафедры терапии и профилактической медицины</p><p>127006, Россия, Москва, ул. Долгоруковская, д. 4</p></bio><bio xml:lang="en"><p>Ekaterina E. Gubernatorova, Cand. Sci. (Med.), Assistant of the Department of Therapy and Preventive Medicine</p><p>4, Dolgorukovskaya St., Moscow, 127006, Russia</p></bio><email xlink:type="simple">creativeone@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-9986-243X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фомина</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Fomina</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фомина Елизавета Игоревна, врач-терапевт участковый</p><p>127572, Россия, Москва, ул. Абрамцевская, д. 16, стр. 1 </p></bio><bio xml:lang="en"><p>Elizaveta I. Fomina, Therapist</p><p>16, Bldg. 1, Abramtsevskaya St., Moscow, 127572, Russia</p></bio><email xlink:type="simple">fomina.elizaveta.i@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3426-1853</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лобанова</surname><given-names>Е. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Lobanova</surname><given-names>E. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лобанова Елена Георгиевна, д.м.н., профессор кафедры фармакологии</p><p>127006, Россия, Москва, ул. Долгоруковская, д. 4</p></bio><bio xml:lang="en"><p>Elena G. Lobanova, Dr. Sci. (Med.), Professor of the Department of Pharmocology</p><p>20, Bldg. 1, Delegatskaya St., Moscow, 127473, Russia</p></bio><email xlink:type="simple">e.g.lobanova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский университет медицины (РосУниМед)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian University of Medicine (ROSUNIMED)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Диагностический центр № 5 с поликлиническим отделением</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Diagnostic Center No. 5 with Polyclinic Department</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>11</month><year>2025</year></pub-date><volume>0</volume><issue>16</issue><elocation-id>128–141</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Адашева Т.В., Губернаторова Е.Е., Фомина Е.И., Лобанова Е.Г., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Адашева Т.В., Губернаторова Е.Е., Фомина Е.И., Лобанова Е.Г.</copyright-holder><copyright-holder xml:lang="en">Adasheva T.V., Gubernatorova E.E., Fomina E.I., Lobanova E.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/9535">https://www.med-sovet.pro/jour/article/view/9535</self-uri><abstract><p>Предиабет (ПД) является ярким представителем состояний, именуемых в современной клинической медицине предболезнями. Распространенность нарушений углеводного обмена увеличивается с каждым годом. Патофизиологические изменения при предиабете многочисленны и представлены в том числе на генетическом уровне так называемой «метаболической памятью». Уже на этапе предиабета начинают формироваться изменения со стороны различных органов и систем, характерные для гипергликемии. Цель обзора – представить современные данные по эпидемиологии, патобиологии предиабета, его осложнениям. В статье представлены статистические и прогностические данные по распространенности предиабета, приведены эпидемиологические данные по России и в мире, обсуждаются современные представления о трансформации ранних нарушений углеводного обмена в диабет. Большой раздел посвящен описанию патофизиологии осложнений длительной гипергликемии со стороны сердечно-сосудистой системы, печени, репродуктивной системы, почек, онкогенеза. Представлены патофизиологические и клинические особенности ранних нарушений углеводного обмена – нарушенной гликемии натощак и нарушенной толерантности к глюкозе. В статье обсуждаются механизмы развития метаболической памяти и ее роль в развитии ранних осложнений предиабета. Проанализированы данные последних исследований, изучающих патогенез органных повреждений при предиабете – механизмы развития жировой болезни печени, факторы риска онкогенеза, репродуктивные нарушения, рассматриваются механизмы клеточного старения при предиабете, микрососудистые и макрососудистые осложнения с развитием сердечно-сосудистых заболеваний, патобиология нефропатии. Анализ современных эпидемиологических и прогностических данных, результатов фундаментальных и клинических исследований подтверждает актуальность проблемы ранней диагностики предиабета и обосновывает необходимость активной терапевтический тактики.</p></abstract><trans-abstract xml:lang="en"><p>Prediabetes (PD) is a prominent example of conditions known as pre-existing disease in modern clinical medicine. The prevalence of carbohydrate metabolism disorders increases every year. Pathophysiological changes in prediabetes are numerous and are represented, among other things, at the genetic level, the so-called “metabolic memory”. Already at the prediabetes stage, changes in various organs and systems characteristic of hyperglycemia begin to form. The purpose of the review is to present modern data on the epidemiology, pathobiology of prediabetes, and its complications. The article presents statistical and prognostic data on the prevalence of prediabetes, provides epidemiological data for Russia and the world, and discusses modern ideas about the transformation of early carbohydrate metabolism disorders into diabetes. A large section is devoted to the description of the pathophysiology of complications of long-term hyperglycemia from the cardiovascular system, liver, reproductive system, kidneys, and oncogenesis. The pathophysiological and clinical features of early carbohydrate metabolism disorders – impaired fasting glycemia and impaired glucose tolerance – are presented. The article discusses the mechanisms of metabolic memory development and its role in the development of early complications of prediabetes. The data of the latest studies studying the pathogenesis of organ damage in prediabetes are analyzed – the mechanisms of fatty liver disease development, risk factors for oncogenesis, reproductive disorders, the mechanisms of cellular aging in prediabetes, microvascular and macrovascular complications with the development of cardiovascular diseases, the pathobiology of nephropathy are considered. The analysis of modern epidemiological and prognostic data, the results of fundamental and clinical studies confirms the relevance of the problem of early diagnosis of prediabetes and substantiates the need for active therapeutic tactics.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>нарушенная толерантность к глюкозе</kwd><kwd>нарушенная гликемия натощак</kwd><kwd>инсулинорезистентность</kwd><kwd>факторы риска</kwd><kwd>метаболическая память</kwd></kwd-group><kwd-group xml:lang="en"><kwd>impaired glucose tolerance</kwd><kwd>impaired fasting glucose</kwd><kwd>insulin resistance</kwd><kwd>risk factors</kwd><kwd>metabolic memory</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина ОМ, Мокрышева НГ, Шестакова МВ, Лавренова ЕА и др. Диспансерное наблюдение пациентов с предиабетом врачом-терапевтом в первичном звене здравоохранения. 2-е изд. М.: РОПНИЗ; 2024. 36 с. https://doi.org/10.15829/ROPNIZ-d100-2024. EDN UWWCJR.</mixed-citation><mixed-citation xml:lang="en">Драпкина ОМ, Мокрышева НГ, Шестакова МВ, Лавренова ЕА и др. Диспансерное наблюдение пациентов с предиабетом врачом-терапевтом в первичном звене здравоохранения. 2-е изд. М.: РОПНИЗ; 2024. 36 с. https://doi.org/10.15829/ROPNIZ-d100-2024. EDN UWWCJR.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119.</mixed-citation><mixed-citation xml:lang="en">Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов ИИ, Шестакова МВ, Галстян ГР. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104–112. https://doi.org/10.14341/DM2004116-17.</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016;19(2):104–112. (In Russ.) https://doi.org/10.14341/DM2004116-17.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Баланова ЮА, Шальнова СА, Имаева АЭ, Куценко ВА, Капустина АВ, Евстифеева СЕ и др. Предиабет: распространенность, ассоциации с сердечно-сосудистыми факторами риска и вклад в выживаемость в российской популяции. Кардиоваскулярная терапия и профилактика. 2024;23(5):4022. https://doi.org/10.15829/1728-8800-2024-4022.</mixed-citation><mixed-citation xml:lang="en">Balanova YuA, Shalnova SA, Imaeva AE, Kutsenko VA, Kapustina AV, Evstifeeva SE et al. Prediabetes: prevalence, associations with cardiovascular risk factors and contribution to survival in the Russian population. Cardiovascular Therapy and Prevention. 2024;23(5):4022. (In Russ.) https://doi.org/10.15829/1728-8800-2024-4022.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932–2938. https://doi.org/10.4103/ijo.IJO_1627_21.</mixed-citation><mixed-citation xml:lang="en">Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932–2938. https://doi.org/10.4103/ijo.IJO_1627_21.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA. 2017;317(24):2515–2523. https://doi.org/10.1001/jama.2017.7596.</mixed-citation><mixed-citation xml:lang="en">Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA. 2017;317(24):2515–2523. https://doi.org/10.1001/jama.2017.7596.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L, Peng W, Zhao Z, Zhang M, Shi Z, Song Z et al. Prevalence and Treatment of Diabetes in China, 2013–2018. JAMA. 2021;326(24):2498–2506. https://doi.org/10.1001/jama.2021.22208.</mixed-citation><mixed-citation xml:lang="en">Wang L, Peng W, Zhao Z, Zhang M, Shi Z, Song Z et al. Prevalence and Treatment of Diabetes in China, 2013–2018. JAMA. 2021;326(24):2498–2506. https://doi.org/10.1001/jama.2021.22208.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997. https://doi.org/10.1136/bmj.m997.</mixed-citation><mixed-citation xml:lang="en">Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997. https://doi.org/10.1136/bmj.m997.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes. 2003;52(6):1475–1484. https://doi.org/10.2337/diabetes.52.6.1475.</mixed-citation><mixed-citation xml:lang="en">Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes. 2003;52(6):1475–1484. https://doi.org/10.2337/diabetes.52.6.1475.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24(1):89–94. https://doi.org/10.2337/diacare.24.1.89.</mixed-citation><mixed-citation xml:lang="en">Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24(1):89–94. https://doi.org/10.2337/diacare.24.1.89.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Dagogo-Jack S, Edeoga C, Ebenibo S, Nyenwe E, Wan J. Lack of racial disparity in incident prediabetes and glycemic progression among black and white offspring of parents with type 2 diabetes: the pathobiology of prediabetes in a biracial cohort (POP-ABC) study. J Clin Endocrinol Metab. 2014;99(6):E1078–E1087. https://doi.org/10.1210/jc.2014-1077.</mixed-citation><mixed-citation xml:lang="en">Dagogo-Jack S, Edeoga C, Ebenibo S, Nyenwe E, Wan J. Lack of racial disparity in incident prediabetes and glycemic progression among black and white offspring of parents with type 2 diabetes: the pathobiology of prediabetes in a biracial cohort (POP-ABC) study. J Clin Endocrinol Metab. 2014;99(6):E1078–E1087. https://doi.org/10.1210/jc.2014-1077.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Барбараш ОЛ, Воевода МИ, Галстян ГР, Шестакова МВ, Бойцов СА, Александрова ОЮ и др. Предиабет как междисциплинарная проблема: определение, риски, подходы к диагностике и профилактике сахарного диабета 2 типа и сердечно-сосудистых осложнений. Российский кардиологический журнал. 2019;(4):83–91. https://doi.org/10.15829/1560-4071-2019-4-83-91.</mixed-citation><mixed-citation xml:lang="en">Barbarash OL, Voyevoda MI, Galstyan GR, Shestakova MV, Boytsov SA, Aleksandrova OYu et al. Pre-diabetes as an interdisciplinary problem: definition, risks, approaches to the diagnostics and prevention of type 2 diabetes and cardiovascular complications. Russian Journal of Cardiology. 2019;(4):83–91. (In Russ.) https://doi.org/10.15829/1560-4071-2019-4-83-91.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6):787–794. https://doi.org/10.1172/JCI7231.</mixed-citation><mixed-citation xml:lang="en">Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6):787–794. https://doi.org/10.1172/JCI7231.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Owei I, Umekwe N, Provo C, Wan J, Dagogo-Jack S. Insulin-sensitive and insulin-resistant obese and non-obese phenotypes: role in prediction of incident pre-diabetes in a longitudinal biracial cohort. BMJ Open Diabetes Res Care. 2017;5(1):e000415. https://doi.org/10.1136/bmjdrc-2017-000415.</mixed-citation><mixed-citation xml:lang="en">Owei I, Umekwe N, Provo C, Wan J, Dagogo-Jack S. Insulin-sensitive and insulin-resistant obese and non-obese phenotypes: role in prediction of incident pre-diabetes in a longitudinal biracial cohort. BMJ Open Diabetes Res Care. 2017;5(1):e000415. https://doi.org/10.1136/bmjdrc-2017-000415.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Al Hommos NA, Ebenibo S, Edeoga C, Dagogo-Jack S. Trajectories of Body Weight and Fat Mass in Relation to Incident Prediabetes in a Biracial Cohort of Free-Living Adults. J Endocr Soc. 2020;5(2):bvaa164. https://doi.org/10.1210/jendso/bvaa164.</mixed-citation><mixed-citation xml:lang="en">Al Hommos NA, Ebenibo S, Edeoga C, Dagogo-Jack S. Trajectories of Body Weight and Fat Mass in Relation to Incident Prediabetes in a Biracial Cohort of Free-Living Adults. J Endocr Soc. 2020;5(2):bvaa164. https://doi.org/10.1210/jendso/bvaa164.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–110. https://doi.org/10.2337/diabetes.52.1.102.</mixed-citation><mixed-citation xml:lang="en">Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–110. https://doi.org/10.2337/diabetes.52.1.102.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ma J, Wang Y, Mo M, Lian Z. Association b.etween low birth weight and impaired glucose tolerance in children: a systematic review and metaanalysis. Front Pediatr. 2024;12:1362076. https://doi.org/10.3389/fped.2024.1362076.</mixed-citation><mixed-citation xml:lang="en">Ma J, Wang Y, Mo M, Lian Z. Association b.etween low birth weight and impaired glucose tolerance in children: a systematic review and metaanalysis. Front Pediatr. 2024;12:1362076. https://doi.org/10.3389/fped.2024.1362076.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Perreault L, Færch K. Approaching pre-diabetes. J Diabetes Complications. 2014;28(2):226–233. https://doi.org/10.1016/j.jdiacomp.2013.10.008.</mixed-citation><mixed-citation xml:lang="en">Perreault L, Færch K. Approaching pre-diabetes. J Diabetes Complications. 2014;28(2):226–233. https://doi.org/10.1016/j.jdiacomp.2013.10.008.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, Groop LC. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes. 2000;49(6):975–980. https://doi.org/10.2337/diabetes.49.6.975.</mixed-citation><mixed-citation xml:lang="en">Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, Groop LC. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes. 2000;49(6):975–980. https://doi.org/10.2337/diabetes.49.6.975.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, TemelkovaKurktschiev T. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes. Diabet Med. 2000;17(12):835–840. https://doi.org/10.1046/j.1464-5491.2000.00408.x.</mixed-citation><mixed-citation xml:lang="en">Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, TemelkovaKurktschiev T. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes. Diabet Med. 2000;17(12):835–840. https://doi.org/10.1046/j.1464-5491.2000.00408.x.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Williams JW, Zimmet PZ, Shaw JE, de Courten MP, Cameron AJ, Chitson P et al Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter? Diabet Med. 2003;20(11):915–920. https://doi.org/10.1046/j.1464-5491.2003.01059.x.</mixed-citation><mixed-citation xml:lang="en">Williams JW, Zimmet PZ, Shaw JE, de Courten MP, Cameron AJ, Chitson P et al Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter? Diabet Med. 2003;20(11):915–920. https://doi.org/10.1046/j.1464-5491.2003.01059.x.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006;55(5):1430–1435. https://doi.org/10.2337/db05-1200.</mixed-citation><mixed-citation xml:lang="en">Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006;55(5):1430–1435. https://doi.org/10.2337/db05-1200.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Jani R, Molina M, Matsuda M, Balas B, Chavez A, DeFronzo RA, AbdulGhani M. Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range. Diabetes Care. 2008;31(2):311–315. https://doi.org/10.2337/dc07-1593.</mixed-citation><mixed-citation xml:lang="en">Jani R, Molina M, Matsuda M, Balas B, Chavez A, DeFronzo RA, AbdulGhani M. Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range. Diabetes Care. 2008;31(2):311–315. https://doi.org/10.2337/dc07-1593.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kanat M, Mari A, Norton L, Winnier D, DeFronzo RA, Jenkinson C,AbdulGhani MA. Distinct β-cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes. 2012;61(2):447–453. https://doi.org/10.2337/db11-0995.</mixed-citation><mixed-citation xml:lang="en">Kanat M, Mari A, Norton L, Winnier D, DeFronzo RA, Jenkinson C,AbdulGhani MA. Distinct β-cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes. 2012;61(2):447–453. https://doi.org/10.2337/db11-0995.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kantartzis K, Machann J, Schick F, Fritsche A, Häring HU, Stefan N. The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia. 2010;53(5):882–889. https://doi.org/10.1007/s00125-010-1663-6.</mixed-citation><mixed-citation xml:lang="en">Kantartzis K, Machann J, Schick F, Fritsche A, Häring HU, Stefan N. The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia. 2010;53(5):882–889. https://doi.org/10.1007/s00125-010-1663-6.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Bock G, Dalla Man C, Campioni M, Chittilapilly E, Basu R, Toffolo G et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 2006;55(12):3536–3549. https://doi.org/10.2337/db06-0319.</mixed-citation><mixed-citation xml:lang="en">Bock G, Dalla Man C, Campioni M, Chittilapilly E, Basu R, Toffolo G et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 2006;55(12):3536–3549. https://doi.org/10.2337/db06-0319.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Faerch K, Vaag A, Holst JJ, Glümer C, Pedersen O, Borch-Johnsen K. Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia. 2008;51(5):853–861. https://doi.org/10.1007/s00125-008-0951-x.</mixed-citation><mixed-citation xml:lang="en">Faerch K, Vaag A, Holst JJ, Glümer C, Pedersen O, Borch-Johnsen K. Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia. 2008;51(5):853–861. https://doi.org/10.1007/s00125-008-0951-x.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer C, Pimenta W, Woerle HJ, Van Haeften T, Szoke E, Mitrakou A, Gerich J. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care. 2006;29(8):1909–1914. https://doi.org/10.2337/dc06-0438.</mixed-citation><mixed-citation xml:lang="en">Meyer C, Pimenta W, Woerle HJ, Van Haeften T, Szoke E, Mitrakou A, Gerich J. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care. 2006;29(8):1909–1914. https://doi.org/10.2337/dc06-0438.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Festa A, D’Agostino R Jr, Hanley AJ, Karter AJ, Saad MF, Haffner SM. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes. 2004;53(6):1549–1555. https://doi.org/10.2337/diabetes.53.6.1549.</mixed-citation><mixed-citation xml:lang="en">Festa A, D’Agostino R Jr, Hanley AJ, Karter AJ, Saad MF, Haffner SM. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes. 2004;53(6):1549–1555. https://doi.org/10.2337/diabetes.53.6.1549.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Бирюкова ЕВ, Шинкин МВ, Старшинова АА. Предиабет – актуальная медико-социальная проблема современности. Эффективная фармакотерапия. 2023;19(12):42–50. https://doi.org/10.33978/2307-3586-2023-19-12-42-50.</mixed-citation><mixed-citation xml:lang="en">Biryukova EV, Shinkin MV, Starshinova AA. Prediabetes is an urgent medical and social problem of our time. Effective Pharmacotherapy. 2023;19(12):42–50. (In Russ.) https://doi.org/10.33978/2307-3586-2023-19-12-42-50.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов ИИ, Шестакова МВ. Феномен «метаболической памяти» в прогнозировании риска развития сосудистых осложнений при сахарном диабете. Терапевтический архив. 2015;87(10):4–10. https://doi.org/10.17116/terarkh201587104-10.</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV. The metabolic memory phenomenon in predicting a risk for vascular complications in diabetes mellitus. Terapevticheskii Arkhiv. 2015;87(10):4–10. (In Russ.) https://doi.org/10.17116/terarkh201587104-10.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов ИИ, Петеркова ВА. Руководство по детской эндокринологии. М.: Универсум Паблишинг; 2006. 595 c.</mixed-citation><mixed-citation xml:lang="en">Дедов ИИ, Петеркова ВА. Руководство по детской эндокринологии. М.: Универсум Паблишинг; 2006. 595 c.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009;94(2):410–415. https://doi.org/10.1210/jc.2008-1824.</mixed-citation><mixed-citation xml:lang="en">Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009;94(2):410–415. https://doi.org/10.1210/jc.2008-1824.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Айтбаев КА, Мамутова СК, Муркамилов ИТ, Фомин ВВ, Кудайбергенова ИО, Муркамилова ЖА, Юсупов ФА. Сахарный диабет 2 типа: роль эпигенетических модификаций в патофизиологии и перспективы использования эпигенетической терапии. Бюллетень науки и практики. 2021;7(5):184–203. Режим доступа: https://bulletennauki.ru/gallery/66_17.pdf.</mixed-citation><mixed-citation xml:lang="en">Aitbaev K, Mamutova S, Murkamilov I, Fomin V, Kudaibergenova I, Murkamilova ZH, Yusupov F. Type 2 diabetes mellitus: The role of epigenetic modifications in pathophysiology and prospects for the use of epigenetic therapy. Bulletin of Science and Practice. 2021;7(5):184–203. (In Russ.) Available at: https://bulletennauki.ru/gallery/66_17.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes. Implications for clinical practice. Prim Care. 1999;26(4):771–789. https://doi.org/10.1016/s0095-4543(05)70130-5.</mixed-citation><mixed-citation xml:lang="en">Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes. Implications for clinical practice. Prim Care. 1999;26(4):771–789. https://doi.org/10.1016/s0095-4543(05)70130-5.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537–544. https://doi.org/10.2337/diacare.20.4.537.</mixed-citation><mixed-citation xml:lang="en">Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537–544. https://doi.org/10.2337/diacare.20.4.537.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, IlanneParikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–1350. https://doi.org/10.1056/NEJM200105033441801.</mixed-citation><mixed-citation xml:lang="en">Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, IlanneParikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–1350. https://doi.org/10.1056/NEJM200105033441801.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. https://doi.org/10.1056/NEJMoa012512.</mixed-citation><mixed-citation xml:lang="en">Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. https://doi.org/10.1056/NEJMoa012512.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–297. https://doi.org/10.1007/s00125-005-0097-z.</mixed-citation><mixed-citation xml:lang="en">Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–297. https://doi.org/10.1007/s00125-005-0097-z.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA. 2001;285(16):2109–2113. https://doi.org/10.1001/jama.285.16.2109.</mixed-citation><mixed-citation xml:lang="en">de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA. 2001;285(16):2109–2113. https://doi.org/10.1001/jama.285.16.2109.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Zimmet P. The burden of type 2 diabetes: are we doing enough? Diabetes Metab. 2003;29(4 Pt 2):6S9–6S18. https://doi.org/10.1016/s1262-3636(03)72783-9.</mixed-citation><mixed-citation xml:lang="en">Zimmet P. The burden of type 2 diabetes: are we doing enough? Diabetes Metab. 2003;29(4 Pt 2):6S9–6S18. https://doi.org/10.1016/s1262-3636(03)72783-9.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7(6):452–461. https://doi.org/10.1016/S2213-8587(19)30093-2.</mixed-citation><mixed-citation xml:lang="en">Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7(6):452–461. https://doi.org/10.1016/S2213-8587(19)30093-2.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Richter B, Hemmingsen B, Metzendorf MI, Takwoingi Y. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database Syst Rev. 2018;10(10):CD012661. https://doi.org/10.1002/14651858.CD012661.pub2.</mixed-citation><mixed-citation xml:lang="en">Richter B, Hemmingsen B, Metzendorf MI, Takwoingi Y. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database Syst Rev. 2018;10(10):CD012661. https://doi.org/10.1002/14651858.CD012661.pub2.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Heianza Y, Arase Y, Fujihara K, Tsuji H, Saito K, Hsieh SD et al. Screening for pre-diabetes to predict future diabetes using various cut-off points for HbA(1c) and impaired fasting glucose: the Toranomon Hospital Health Management Center Study 4 (TOPICS 4). Diabet Med. 2012;29(9):e279–e285. https://doi.org/10.1111/j.1464-5491.2012.03686.x.</mixed-citation><mixed-citation xml:lang="en">Heianza Y, Arase Y, Fujihara K, Tsuji H, Saito K, Hsieh SD et al. Screening for pre-diabetes to predict future diabetes using various cut-off points for HbA(1c) and impaired fasting glucose: the Toranomon Hospital Health Management Center Study 4 (TOPICS 4). Diabet Med. 2012;29(9):e279–e285. https://doi.org/10.1111/j.1464-5491.2012.03686.x.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Rajput R, Ahlawat P. Prevalence and predictors of non-alcoholic fatty liver disease in prediabetes. Diabetes Metab Syndr. 2019;13(5):2957–2960. https://doi.org/10.1016/j.dsx.2019.07.060.</mixed-citation><mixed-citation xml:lang="en">Rajput R, Ahlawat P. Prevalence and predictors of non-alcoholic fatty liver disease in prediabetes. Diabetes Metab Syndr. 2019;13(5):2957–2960. https://doi.org/10.1016/j.dsx.2019.07.060.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Бакулин ИГ, Сандлер ЮГ, Винницкая ЕВ, Кейян ВА, Родионова СВ, Ротин ДЛ. Сахарный диабет и неалкогольная жировая болезнь печени: грани сопряженности. Терапевтический архив. 2017;89(2):59–65. https://doi.org/10.17116/terarkh201789259-65.</mixed-citation><mixed-citation xml:lang="en">Bakulin IG, Sandler YG, Vinnitskayа EV, Keiyan VA, Rodionova SV, Rotin DL. Diabetes mellitus and nonalcoholic fatty liver disease: The verges of contingency. Terapevticheskii Arkhiv. 2017;89(2):59–65. (In Russ.) https://doi.org/10.17116/terarkh201789259-65.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Richard J, Lingvay I. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther. 2011;9(3):321–328. https://doi.org/10.1586/erc.11.15.</mixed-citation><mixed-citation xml:lang="en">Richard J, Lingvay I. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther. 2011;9(3):321–328. https://doi.org/10.1586/erc.11.15.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of Insulin Resistance in MAFLD. Int J Mol Sci. 2021;22(8):4156. https://doi.org/10.3390/ijms22084156.</mixed-citation><mixed-citation xml:lang="en">Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of Insulin Resistance in MAFLD. Int J Mol Sci. 2021;22(8):4156. https://doi.org/10.3390/ijms22084156.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Y, Cai X, Qiu M, Chen P, Tang H, Hu Y, Huang Y. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia. 2014;57(11):2261–2269. https://doi.org/10.1007/s00125-014-3361-2.</mixed-citation><mixed-citation xml:lang="en">Huang Y, Cai X, Qiu M, Chen P, Tang H, Hu Y, Huang Y. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia. 2014;57(11):2261–2269. https://doi.org/10.1007/s00125-014-3361-2.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Ramteke P, Deb A, Shepal V, Bhat MK. Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality. Cancers. 2019;11(9):1402. https://doi.org/10.3390/cancers11091402.</mixed-citation><mixed-citation xml:lang="en">Ramteke P, Deb A, Shepal V, Bhat MK. Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality. Cancers. 2019;11(9):1402. https://doi.org/10.3390/cancers11091402.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Dankner R, Boffetta P, Balicer RD, Boker LK, Sadeh M, Berlin A et al. TimeDependent Risk of Cancer After a Diabetes Diagnosis in a Cohort of 2.3 Million Adults. Am J Epidemiol. 2016;183(12):1098–1106. https://doi.org/10.1093/aje/kwv290.</mixed-citation><mixed-citation xml:lang="en">Dankner R, Boffetta P, Balicer RD, Boker LK, Sadeh M, Berlin A et al. TimeDependent Risk of Cancer After a Diabetes Diagnosis in a Cohort of 2.3 Million Adults. Am J Epidemiol. 2016;183(12):1098–1106. https://doi.org/10.1093/aje/kwv290.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Colloca A, Donisi I, Anastasio C, Balestrieri ML, D’Onofrio N. Metabolic Alteration Bridging the Prediabetic State and Colorectal Cancer. Cells. 2024;13(8):663. https://doi.org/10.3390/cells13080663.</mixed-citation><mixed-citation xml:lang="en">Colloca A, Donisi I, Anastasio C, Balestrieri ML, D’Onofrio N. Metabolic Alteration Bridging the Prediabetic State and Colorectal Cancer. Cells. 2024;13(8):663. https://doi.org/10.3390/cells13080663.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J, Zou S, Fang L. Metabolic reprogramming in colorectal cancer: regulatory networks and therapy. Cell Biosci. 2023;13(1):25. https://doi.org/10.1186/s13578-023-00977-w.</mixed-citation><mixed-citation xml:lang="en">Zhang J, Zou S, Fang L. Metabolic reprogramming in colorectal cancer: regulatory networks and therapy. Cell Biosci. 2023;13(1):25. https://doi.org/10.1186/s13578-023-00977-w.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes. 2007;14(3):226–234. https://doi.org/10.1097/MED.0b013e32814db856.</mixed-citation><mixed-citation xml:lang="en">Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes. 2007;14(3):226–234. https://doi.org/10.1097/MED.0b013e32814db856.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol. 2010;12(4):e157–e180. Available at: https://pubmed.ncbi.nlm.nih.gov/21234260/.</mixed-citation><mixed-citation xml:lang="en">Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol. 2010;12(4):e157–e180. Available at: https://pubmed.ncbi.nlm.nih.gov/21234260/.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Тюзиков ИА. Метаболический синдром и мужское бесплодие (обзор литературы). Андрология и генитальная хирургия. 2013;14(2):5–10. Режим доступа: https://www.elibrary.ru/rrwnfz.</mixed-citation><mixed-citation xml:lang="en">Tyuzikov IA. Metabolic syndrome and male infertility (review). Andrology and Genital Surgery. 2013;14(2):5–10. (In Russ.) Available at: https://www.elibrary.ru/rrwnfz.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen RH, Wilcox AJ, Skjaerven R, Baird DD. Men’s body mass index and infertility. Hum Reprod. 2007;22(9):2488–2493. https://doi.org/10.1093/humrep/dem139.</mixed-citation><mixed-citation xml:lang="en">Nguyen RH, Wilcox AJ, Skjaerven R, Baird DD. Men’s body mass index and infertility. Hum Reprod. 2007;22(9):2488–2493. https://doi.org/10.1093/humrep/dem139.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Тюзиков ИА, Калинченко СЮ, Ворслов ЛО, Тишова ЮА. Мужское бесплодие и инсулинорезистентность: есть ли патогенетические связи и кто, когда и как должен диагностировать и лечить их? Экспериментальная и клиническая урология. 2014;(2):68–76. Режим доступа: https://www.elibrary.ru/sjwgcr.</mixed-citation><mixed-citation xml:lang="en">Tyuzikov IA, Kalinchenko SYu, Vorslov LO, Tishova YuA. Male infertility and insulin resistance: are there any pathogenic links, and who, when and how must diagnose and treat them? Experimental and Clinical Urology. 2014;(2):68–76. (In Russ.) Available at: https://www.elibrary.ru/sjwgcr.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Андреева ЕН, Карпова ЕА, Деркач ДА, Веснина АФ, Пономарева ТА, Шмелева ОО. Влияние инсулина на функцию яичников. Проблемы репродукции. 2005;(4):27–34. Режим доступа: http://elib.fesmu.ru/Article.aspx?id=133606.</mixed-citation><mixed-citation xml:lang="en">Andreeva EN, Karpova EA, Derkach DA, Vesnina AF, Ponomareva TA, Shmeleva OO. Influence of insulin on function of ovaries. Reproduction problems. 2005;(4):27–34. (In Russ.) Available at: http://elib.fesmu.ru/Article.aspx?id=133606.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов ИИ, Мельниченко ГА. Синдром поликистозных яичников. М.: МИА; 2007. 361 с.</mixed-citation><mixed-citation xml:lang="en">Manukhin IB, Gevorkyan MA, Chagay NB. Androgens and insulin resistance (review of literature). Russian Journal of Human Reproduction. 2005;11(2):27–31. (In Russ.) Available at: https://elibrary.ru/hskcar.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Манухин ИБ, Геворкян МА, Чагай НБ. Андрогены и инсулинорезистентность (обзор литературы). Проблемы репродукции. 2005;11(2):27–31. Режим доступа: https://elibrary.ru/hskcar.</mixed-citation><mixed-citation xml:lang="en">Sadeghi HM, Adeli I, Calina D, Docea AO, Mousavi T, Daniali M et al. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. Int J Mol Sci. 2022;23(2):583. https://doi.org/10.3390/ijms23020583.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Sadeghi HM, Adeli I, Calina D, Docea AO, Mousavi T, Daniali M et al. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. Int J Mol Sci. 2022;23(2):583. https://doi.org/10.3390/ijms23020583.</mixed-citation><mixed-citation xml:lang="en">Ovsyannikova TV, Demidova IYu, Glazkova OI. Gonadotrophic function of insulin. Giperandrogeniya and giperinsulinemiya (review of literature). Russian Journal of Human Reproduction. 1998;(6):5–8. (In Russ.) Available at: https://rusmedserv.com/problreprod/1998g/6/article_640.html.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Овсянникова ТВ, Демидова ИЮ, Глазкова ОИ. Гонадотропная функция инсулина. Гиперандрогения и гиперинсулинемия (обзор литературы). Проблемы репродукции. 1998;(6):5–8. Режим доступа: https://rusmedserv.com/problreprod/1998g/6/article_640.html.</mixed-citation><mixed-citation xml:lang="en">Mkrtumyan AM, Chagay NB. The relationship between ovarian hormones, fat mass and insulin resistance. Russian Journal of Human Reproduction. 2005;(5): 55–59. (In Russ.) Available at: http://elib.fesmu.ru/Article.aspx?id=137961.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Мкртумян АМ, Чагай НБ. Взаимосвязь между гормонами яичников, массой жировой ткани и инсулинорезистентностью. Проблемы репродукции. 2005;(5):55–59. Режим доступа: http://elib.fesmu.ru/Article.aspx?id=137961.</mixed-citation><mixed-citation xml:lang="en">Daubenmier J, Lin J, Blackburn E, Hecht FM, Kristeller J, Maninger N et al. Changes in stress, eating, and metabolic factors are related to changes in telomerase activity in a randomized mindfulness intervention pilot study. Psychoneuroendocrinology. 2012;37(7):917–928. https://doi.org/10.1016/j.psyneuen.2011.10.008.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Daubenmier J, Lin J, Blackburn E, Hecht FM, Kristeller J, Maninger N et al. Changes in stress, eating, and metabolic factors are related to changes in telomerase activity in a randomized mindfulness intervention pilot study. Psychoneuroendocrinology. 2012;37(7):917–928. https://doi.org/10.1016/j.psyneuen.2011.10.008.</mixed-citation><mixed-citation xml:lang="en">Dudinskaya EN, Brailova NV, Strazhesko ID, Akasheva DU, Tkacheva ON, Shestakova MV. Role of insulin resistance in vascular aging processes (a review of literature). Profilakticheskaya Meditsina. 2014;17(2):35–41. (In Russ.) Available at: https://www.mediasphera.ru/issues/profilakticheskaya-meditsina/2014/2/031726-6130201426.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Дудинская ЕН, Браилова НВ, Стражеско ИД, Акашева ДУ, Ткачева ОН, Шестакова МВ. Роль инсулинорезистентности в процессах сосудистого старения (обзор литературы). Профилактическая медицина. 2014;17(2):35–41. Режим доступа: https://www.mediasphera.ru/issues/profilakticheskaya-meditsina/2014/2/031726-6130201426.</mixed-citation><mixed-citation xml:lang="en">Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF et al. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005;366(9486):662–664. https://doi.org/10.1016/S0140-6736(05)66630-5.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF et al. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005;366(9486):662–664. https://doi.org/10.1016/S0140-6736(05)66630-5.</mixed-citation><mixed-citation xml:lang="en">Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010;55(13):1310–1317. https://doi.org/10.1016/j.jacc.2009.10.060.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010;55(13):1310–1317. https://doi.org/10.1016/j.jacc.2009.10.060.</mixed-citation><mixed-citation xml:lang="en">Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008;31(3):464–469. https://doi.org/10.2337/dc07-1796.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008;31(3):464–469. https://doi.org/10.2337/dc07-1796.</mixed-citation><mixed-citation xml:lang="en">Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035–3087. https://doi.org/10.1093/eurheartj/eht108.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035–3087. https://doi.org/10.1093/eurheartj/eht108.</mixed-citation><mixed-citation xml:lang="en">Makino N, Sasaki M, Maeda T, Mimori K. Telomere biology in cardiovascular disease – role of insulin sensitivity in diabetic hearts. Exp Clin Cardiol. 2010;15(4): e128–e133.Available at: https://pubmed.ncbi.nlm.nih.gov/21264070/.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Makino N, Sasaki M, Maeda T, Mimori K. Telomere biology in cardiovascular disease – role of insulin sensitivity in diabetic hearts. Exp Clin Cardiol. 2010;15(4): e128–e133.Available at: https://pubmed.ncbi.nlm.nih.gov/21264070/.</mixed-citation><mixed-citation xml:lang="en">Demidova TYu, Plakhotnyaya VM. Prediabetes: a risk factor for cardiovascular diseases and a window of opportunity for their prevention. FOCUS. Endocrinology. 2023;4(2):6–11. (In Russ.) https://doi.org/10.15829/1560-4071-2023-24.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Демидова ТЮ, Плахотняя ВМ. Предиабет: фактор риска сердечно-сосудистых заболеваний и «окно возможностей» для их профилактики. FOCUS Эндокринология. 2023;4(2):6–11. https://doi.org/10.15829/1560-4071-2023-24.</mixed-citation><mixed-citation xml:lang="en">Jaquenod De Giusti C, Palomeque J, Mattiazzi A. Ca2+ mishandling and mitochondrial dysfunction: a converging road to prediabetic and diabetic cardiomyopathy. Pflugers Arch. 2022;474(1):33–61. https://doi.org/10.1007/s00424-021-02650-y.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Jaquenod De Giusti C, Palomeque J, Mattiazzi A. Ca2+ mishandling and mitochondrial dysfunction: a converging road to prediabetic and diabetic cardiomyopathy. Pflugers Arch. 2022;474(1):33–61. https://doi.org/10.1007/s00424-021-02650-y.</mixed-citation><mixed-citation xml:lang="en">Ali MK, Bullard KM, Saydah S, Imperatore G, Gregg EW. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988–2014. Lancet Diabetes Endocrinol. 2018;6(5):392–403. https://doi.org/10.1016/S2213-8587(18)30027-5.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Ali MK, Bullard KM, Saydah S, Imperatore G, Gregg EW. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988–2014. Lancet Diabetes Endocrinol. 2018;6(5):392–403. https://doi.org/10.1016/S2213-8587(18)30027-5.</mixed-citation><mixed-citation xml:lang="en">Cai X, Zhang Y, Li M, Wu JH, Mai L, Li J et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297. https://doi.org/10.1136/bmj.m2297.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Cai X, Zhang Y, Li M, Wu JH, Mai L, Li J et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297. https://doi.org/10.1136/bmj.m2297.</mixed-citation><mixed-citation xml:lang="en">Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999;354(9179):617–621. Available at: https://pubmed.ncbi.nlm.nih.gov/10466661/.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999;354(9179):617–621. Available at: https://pubmed.ncbi.nlm.nih.gov/10466661/.</mixed-citation><mixed-citation xml:lang="en">Sorkin JD, Muller DC, Fleg JL,Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care. 2005;28(11):2626–2632. https://doi.org/10.2337/diacare.28.11.2626.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Sorkin JD, Muller DC, Fleg JL,Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care. 2005;28(11):2626–2632. https://doi.org/10.2337/diacare.28.11.2626.</mixed-citation><mixed-citation xml:lang="en">Nakagami T; DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47(3):385–394. https://doi.org/10.1007/s00125-004-1334-6.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Nakagami T; DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47(3):385–394. https://doi.org/10.1007/s00125-004-1334-6.</mixed-citation><mixed-citation xml:lang="en">Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care. 2001;24(3):447–453. https://doi.org/10.2337/diacare.24.3.447.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care. 2001;24(3):447–453. https://doi.org/10.2337/diacare.24.3.447.</mixed-citation><mixed-citation xml:lang="en">Barr ELM, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia. 2009;52(3):415–424. https://doi.org/10.1007/s00125-008-1246-y.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Barr ELM, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia. 2009;52(3):415–424. https://doi.org/10.1007/s00125-008-1246-y.</mixed-citation><mixed-citation xml:lang="en">Wen CP, Cheng TY, Tsai SP, Hsu HL, Wang SL. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care. 2005;28(11):2756–2761. https://doi.org/10.2337/diacare.28.11.2756.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Wen CP, Cheng TY, Tsai SP, Hsu HL, Wang SL. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care. 2005;28(11):2756–2761. https://doi.org/10.2337/diacare.28.11.2756.</mixed-citation><mixed-citation xml:lang="en">Warren B, Pankow JS, Matsushita K, Punjabi NM, Daya NR, Grams M et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2017;5(1):34–42. https://doi.org/10.1016/S2213-8587(16)30321-7.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Warren B, Pankow JS, Matsushita K, Punjabi NM, Daya NR, Grams M et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2017;5(1):34–42. https://doi.org/10.1016/S2213-8587(16)30321-7.</mixed-citation><mixed-citation xml:lang="en">Schneider AL, Kalyani RR, Golden S, Stearns SC, Wruck L, Yeh HC et al. Diabetes and Prediabetes and Risk of Hospitalization: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2016;39(5):772–779. https://doi.org/10.2337/dc15-1335.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Schneider AL, Kalyani RR, Golden S, Stearns SC, Wruck L, Yeh HC et al. Diabetes and Prediabetes and Risk of Hospitalization: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2016;39(5):772–779. https://doi.org/10.2337/dc15-1335.</mixed-citation><mixed-citation xml:lang="en">Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007;24(2):137–144. https://doi.org/10.1111/j.1464-5491.2007.02043.x.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007;24(2):137–144. https://doi.org/10.1111/j.1464-5491.2007.02043.x.</mixed-citation><mixed-citation xml:lang="en">Katon JG, Reiber GE, Nelson KM. Peripheral neuropathy defined by monofilament insensitivity and diabetes status: NHANES 1999-2004. Diabetes Care. 2013;36(6):1604–1606. https://doi.org/10.2337/dc12-1102.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Katon JG, Reiber GE, Nelson KM. Peripheral neuropathy defined by monofilament insensitivity and diabetes status: NHANES 1999-2004. Diabetes Care. 2013;36(6):1604–1606. https://doi.org/10.2337/dc12-1102.</mixed-citation><mixed-citation xml:lang="en">Plantinga LC, Crews DC, Coresh J, Miller ER 3rd, Saran R, Yee J et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5(4):673–682. https://doi.org/10.2215/CJN.07891109.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Plantinga LC, Crews DC, Coresh J, Miller ER 3rd, Saran R, Yee J et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5(4):673–682. https://doi.org/10.2215/CJN.07891109.</mixed-citation><mixed-citation xml:lang="en">van Bussel FC, Backes WH, van Veenendaal TM, Hofman PA, van Boxtel MP, Schram MT et al. Functional Brain Networks Are Altered in Type 2 Diabetes and Prediabetes: Signs for Compensation of Cognitive Decrements? The Maastricht Study. Diabetes. 2016;65(8):2404–2413. https://doi.org/10.2337/db16-0128.</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">van Bussel FC, Backes WH, van Veenendaal TM, Hofman PA, van Boxtel MP, Schram MT et al. Functional Brain Networks Are Altered in Type 2 Diabetes and Prediabetes: Signs for Compensation of Cognitive Decrements? The Maastricht Study. Diabetes. 2016;65(8):2404–2413. https://doi.org/10.2337/db16-0128.</mixed-citation><mixed-citation xml:lang="en">van Agtmaal MJM, Houben AJHM, de Wit V, Henry RMA, Schaper NC, Dagnelie PC et al. Prediabetes Is Associated With Structural Brain Abnormalities: The Maastricht Study. Diabetes Care. 2018;41(12):2535–2543. https://doi.org/10.2337/dc18-1132.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">van Agtmaal MJM, Houben AJHM, de Wit V, Henry RMA, Schaper NC, Dagnelie PC et al. Prediabetes Is Associated With Structural Brain Abnormalities: The Maastricht Study. Diabetes Care. 2018;41(12):2535–2543. https://doi.org/10.2337/dc18-1132.</mixed-citation><mixed-citation xml:lang="en">Erekat NS. Programmed Cell Death in Diabetic Nephropathy: A Review of Apoptosis, Autophagy, and Necroptosis. Med Sci Monit. 2022;28:e937766. https://doi.org/10.12659/MSM.937766.</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Erekat NS. Programmed Cell Death in Diabetic Nephropathy: A Review of Apoptosis, Autophagy, and Necroptosis. Med Sci Monit. 2022;28:e937766. https://doi.org/10.12659/MSM.937766.</mixed-citation><mixed-citation xml:lang="en">Erekat NS. Programmed Cell Death in Diabetic Nephropathy: A Review of Apoptosis, Autophagy, and Necroptosis. Med Sci Monit. 2022;28:e937766. https://doi.org/10.12659/MSM.937766.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
